帕金森病——现代治疗方法综述

O. Chyniak, O. Dubenko, Olexander Potapov, A. Shulga, A. Kotsyuba
{"title":"帕金森病——现代治疗方法综述","authors":"O. Chyniak, O. Dubenko, Olexander Potapov, A. Shulga, A. Kotsyuba","doi":"10.21272/eumj.2023;11(1):1-13","DOIUrl":null,"url":null,"abstract":"Introduction. Parkinson's disease (PD) is a neurodegenerative neurological disease with a slowly progressive course. In particular, it manifests as a movement disorder that includes rest tremor, rigidity, bradykinesia, and postural instability. Movement disorder in patients with PD mainly occurs due to the selective loss of pigmented dopaminergic neurons of the compact area of the substantia nigra, as a result of the depletion of dopamine in the striatum. The pathogenetic feature of this disease is the presence of intraneuronal aggregates and inclusions of α-synuclein. To date, there are no proven treatments for Parkinson's disease, but a number of medications exist offering benefits in terms of controlling movement disorders. Although they can significantly improve motor function, they can also lead to problematic side effects, especially as the disease progresses.\nMaterials and methods. To analyze the main directions of modern methods of Parkinson's disease treatment and to conduct a profound review and analysis of literature research data on the modern methods of Parkinson's disease treatment over the past 10 years.\nThe results. It has been established that modern treatment methods are based mainly on exogenous administration of drugs with dopaminergic activity and inhibitors of endogenous dopamine metabolism. Although levodopa has been used in the treatment of Parkinson's disease since its inception, numerous experimental therapeutic and neurosurgical approaches are now being investigated. These include drugs aiming at the inhibition and degradation of α-synuclein aggregation, which is considered the driving force of neurodegeneration in Parkinson's disease. They raise expectations that a disease-modifying agent will be discovered in the short-term future. Thus, in combination with a number of regenerative and neurosurgical approaches, including stem cell and gene therapy and deep brain stimulation, significant progress will be made in the treatment of Parkinson's disease in the coming years and a number of new effective options will become available.","PeriodicalId":315243,"journal":{"name":"Eastern Ukrainian Medical Journal","volume":"13 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PARKINSON'S DISEASE — OVERVIEW OF MODERN TREATMENT METHODS\",\"authors\":\"O. Chyniak, O. Dubenko, Olexander Potapov, A. Shulga, A. Kotsyuba\",\"doi\":\"10.21272/eumj.2023;11(1):1-13\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction. Parkinson's disease (PD) is a neurodegenerative neurological disease with a slowly progressive course. In particular, it manifests as a movement disorder that includes rest tremor, rigidity, bradykinesia, and postural instability. Movement disorder in patients with PD mainly occurs due to the selective loss of pigmented dopaminergic neurons of the compact area of the substantia nigra, as a result of the depletion of dopamine in the striatum. The pathogenetic feature of this disease is the presence of intraneuronal aggregates and inclusions of α-synuclein. To date, there are no proven treatments for Parkinson's disease, but a number of medications exist offering benefits in terms of controlling movement disorders. Although they can significantly improve motor function, they can also lead to problematic side effects, especially as the disease progresses.\\nMaterials and methods. To analyze the main directions of modern methods of Parkinson's disease treatment and to conduct a profound review and analysis of literature research data on the modern methods of Parkinson's disease treatment over the past 10 years.\\nThe results. It has been established that modern treatment methods are based mainly on exogenous administration of drugs with dopaminergic activity and inhibitors of endogenous dopamine metabolism. Although levodopa has been used in the treatment of Parkinson's disease since its inception, numerous experimental therapeutic and neurosurgical approaches are now being investigated. These include drugs aiming at the inhibition and degradation of α-synuclein aggregation, which is considered the driving force of neurodegeneration in Parkinson's disease. They raise expectations that a disease-modifying agent will be discovered in the short-term future. Thus, in combination with a number of regenerative and neurosurgical approaches, including stem cell and gene therapy and deep brain stimulation, significant progress will be made in the treatment of Parkinson's disease in the coming years and a number of new effective options will become available.\",\"PeriodicalId\":315243,\"journal\":{\"name\":\"Eastern Ukrainian Medical Journal\",\"volume\":\"13 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Eastern Ukrainian Medical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.21272/eumj.2023;11(1):1-13\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eastern Ukrainian Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21272/eumj.2023;11(1):1-13","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

介绍。帕金森病(PD)是一种缓慢进展的神经退行性疾病。特别是,它表现为运动障碍,包括静止性震颤、僵硬、运动迟缓和姿势不稳定。PD患者的运动障碍主要是由于纹状体多巴胺耗损导致黑质致密区色素多巴胺能神经元选择性丢失。这种疾病的发病特征是α-突触核蛋白在神经元内聚集和包涵体的存在。到目前为止,还没有证实的治疗帕金森病的方法,但是有一些药物在控制运动障碍方面提供了好处。虽然它们可以显著改善运动功能,但它们也会导致问题的副作用,特别是随着疾病的进展。材料和方法。分析现代帕金森病治疗方法的主要方向,对近10年来现代帕金森病治疗方法的文献研究资料进行深入的回顾和分析。结果。已经确定,现代治疗方法主要基于外源性给予具有多巴胺能活性和内源性多巴胺代谢抑制剂的药物。虽然左旋多巴从一开始就被用于治疗帕金森病,但目前正在研究许多实验性治疗和神经外科方法。其中包括旨在抑制和降解α-突触核蛋白聚集的药物,α-突触核蛋白聚集被认为是帕金森病神经退行性变的驱动力。它们提高了人们对在不久的将来会发现一种疾病调节剂的期望。因此,结合一些再生和神经外科方法,包括干细胞和基因治疗以及深部脑刺激,帕金森病的治疗将在未来几年取得重大进展,并将出现一些新的有效选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
PARKINSON'S DISEASE — OVERVIEW OF MODERN TREATMENT METHODS
Introduction. Parkinson's disease (PD) is a neurodegenerative neurological disease with a slowly progressive course. In particular, it manifests as a movement disorder that includes rest tremor, rigidity, bradykinesia, and postural instability. Movement disorder in patients with PD mainly occurs due to the selective loss of pigmented dopaminergic neurons of the compact area of the substantia nigra, as a result of the depletion of dopamine in the striatum. The pathogenetic feature of this disease is the presence of intraneuronal aggregates and inclusions of α-synuclein. To date, there are no proven treatments for Parkinson's disease, but a number of medications exist offering benefits in terms of controlling movement disorders. Although they can significantly improve motor function, they can also lead to problematic side effects, especially as the disease progresses. Materials and methods. To analyze the main directions of modern methods of Parkinson's disease treatment and to conduct a profound review and analysis of literature research data on the modern methods of Parkinson's disease treatment over the past 10 years. The results. It has been established that modern treatment methods are based mainly on exogenous administration of drugs with dopaminergic activity and inhibitors of endogenous dopamine metabolism. Although levodopa has been used in the treatment of Parkinson's disease since its inception, numerous experimental therapeutic and neurosurgical approaches are now being investigated. These include drugs aiming at the inhibition and degradation of α-synuclein aggregation, which is considered the driving force of neurodegeneration in Parkinson's disease. They raise expectations that a disease-modifying agent will be discovered in the short-term future. Thus, in combination with a number of regenerative and neurosurgical approaches, including stem cell and gene therapy and deep brain stimulation, significant progress will be made in the treatment of Parkinson's disease in the coming years and a number of new effective options will become available.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.10
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信